ArticleNature communications2016
Establishment of human iPSC-based models for the study and targeting of glioma initiating cells.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 76 citations in OpenAlex.
- Decoding glioblastoma evolution and heterogeneity through mechanistic modeling: implications for clinical translation.Journal of experimental & clinical cancer research : CR · 2026Review
- Tumor organoids as a revolutionary platform for advancing cancer nanomedicine.Molecular cancer · 2026Review
- Review
- An induced pluripotent stem cell model of Schwann cell differentiation reveals NF2- related gene regulatory networks.Research square · 2025Article
- Unlocking the Potential of Induced Pluripotent Stem Cells in Revolutionizing Cancer Therapy.Current stem cell research & therapy · 2025Review
- Brain tumors and induced pluripotent stem cell technology: a systematic review of the literature.Annals of medicine and surgery (2012) · 2025Article
- Unraveling Glioblastoma: TME Implication and Gene Therapy Advances.Current gene therapy · 2025Review
- AI in cellular engineering and reprogramming.Biophysical journal · 2024Review
- Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.International journal of molecular sciences · 2024Review
- Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Engineering prostate cancer in vitro: what does it take?Oncogene · 2023Review
- Modeling brain and neural crest neoplasms with human pluripotent stem cells.Neuro-oncology · 2023Review
- ActivatedInternational journal of oncology · 2023Article
- Modeling nervous system tumors with human stem cells and organoids.Cell regeneration (London, England) · 2023Review
- Modeling Human Brain Tumors and the Microenvironment Using Induced Pluripotent Stem Cells.Cancers · 2023Review
- Glioblastoma modeling with 3D organoids: progress and challenges.Oxford open neuroscience · 2023Review
- Xeno-free induced pluripotent stem cell-derived neural progenitor cells for in vivo applications.Journal of translational medicine · 2022Article
- Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling.Acta neuropathologica communications · 2022Article
- The epigenetic-metabolic interplay in gliomagenesis.Open biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 3 countries.
Funding
Abstract
Glioma tumour-initiating cells (GTICs) can originate upon the transformation of neural progenitor cells (NPCs). Studies on GTICs have focused on primary tumours from which GTICs could be isolated and the use of human embryonic material. Recently, the somatic genomic landscape of human gliomas has been reported. RTK (receptor tyrosine kinase) and p53 signalling were found dysregulated in ∼90% and 86% of all primary tumours analysed, respectively. Here we report on the use of human-induced pluripotent stem cells (hiPSCs) for modelling gliomagenesis. Dysregulation of RTK and p53 signalling in hiPSC-derived NPCs (iNPCs) recapitulates GTIC properties in vitro. In vivo transplantation of transformed iNPCs leads to highly aggressive tumours containing undifferentiated stem cells and their differentiated derivatives. Metabolic modulation compromises GTIC viability. Last, screening of 101 anti-cancer compounds identifies three molecules specifically targeting transformed iNPCs and primary GTICs. Together, our results highlight the potential of hiPSCs for studying human tumourigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.